// App-Quantinova.ai

4077 : Final results of a phase III randomized controlled trial comparing modified gemcitabine + oxaliplatin (mGEMOX) to gemcitabine+ cisplatin in management of unresectable gall bladder cancer (GBC).

Researchers

Presenter

  • Atul Sharma

Principal Investigators

  • Nootan Kumar Shukla

  • Surendra Pal Chaudhary

  • Ranjit Sahoo

  • BK Mohanti

  • S. V. S. Deo

  • Sujoy Pal

  • Sanjay Thulkar

  • Sunil Kumar

  • Sushmita Pathy

  • Peush Sahni

  • Sreenivas Vishnubhatla

  • Sushma Bhatnagar

  • Nihar Ranjan Dash

  • Rakesh Kumar

  • Vinod Raina

  • Venkateswaran K Iyer

  • Seema Mishra

Medical Centers

  • All India Institute of Medical Sciences, New Delhi, India

  • Department of Surgical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

  • Room no 216 2nd Floor Inst Rotary Cancer Hospital, New Delhi, India

  • AIIMS, New Delhi, India

  • Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

  • Institute Rotary Cancer Hospital, AIIMS, New Delhi, India

  • Department of Surgical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

  • Dept of Surgical Oncology,Dr BRA.Institute Rotary Cancer Hospital, New Delhi, India

  • Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India

  • Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India

  • FMRI, New Delhi, India

  • Dept of Anesthesia,Dr.BRA.Institute Rotary Cancer Hospital, New Delhi, India

Locations

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gallbladder cancer

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Oxaliplatin

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

  • Single Center

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved